• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

Antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer

June 2, 2025
in Medical Research
Reading Time: 3 mins read
A A
0
ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter


ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer. Credit: The University of Texas MD Anderson Cancer Center

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to data from a Phase I/II study led by researchers from The University of Texas MD Anderson Cancer Center.

These results suggest that PVEK should be considered a potential new standard treatment option for patients with BPDCN, a rare, aggressive blood cancer that involves the skin, bone marrow and lymph nodes.

Findings from the CADENZA study were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting by Naveen Pemmaraju, who led the trial together with Naval Daver.

As a frontline treatment in 33 newly diagnosed patients with BPDCN, researchers observed an overall response rate of 85%, including a complete response rate of 70% with a median overall survival of 16.6 months.

“Patients with BPDCN are in need of improved frontline therapies to treat their disease, so we’re very excited to see this trial going extremely well in terms of safety and efficacy,” Pemmaraju said. “The responses we have observed make PVEK a strong candidate as a standard-of-care treatment.”

The current standard-of-care treatment for patients with BPDCN is tagraxofusp-erzs, which targets CD123 found at high levels on certain cancer cells, including BPDCN. MD Anderson researchers helped advance tagraxofusp-erzs toward Food and Drug Administration approval in 2018.

PVEK represents a next generation of CD123-targeted treatment. As an ADC, it works by delivering a drug directly to cancer cells by targeting CD123 on the surface of BPDCN cells, resulting in death of the cancer cells.

The global multi-center trial enrolled a total of 84 adult patients with CD123-positive BPDCN. Of these patients, 33 patients were newly diagnosed, and 51 patients had relapsed or refractory BPDCN with one, two or three prior lines of therapy. Participants received the therapy intravenously on day one of a 21-day cycle in an outpatient setting.

The most common side effects included peripheral edema, which was reversible and found to be manageable.

Given the results of this trial, there is potential for investigating combination therapies of CD123-targeted agent PVEK with other treatments active in BPDCN in future clinical trials, Pemmaraju explained.

The clinical trial was funded by AbbVie. Pemmaraju has served on the advisory board and as a consultant for AbbVie. Daver has received research support and has served on the advisory board and as a consultant for AbbVie.

More information:
Abstract: meetings.asco.org/abstracts-presentations/244202

Provided by
University of Texas M. D. Anderson Cancer Center


Citation:
Antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer (2025, June 2)
retrieved 2 June 2025
from https://medicalxpress.com/news/2025-06-antibody-drug-conjugate-safety-response.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer. Credit: The University of Texas MD Anderson Cancer Center

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to data from a Phase I/II study led by researchers from The University of Texas MD Anderson Cancer Center.

These results suggest that PVEK should be considered a potential new standard treatment option for patients with BPDCN, a rare, aggressive blood cancer that involves the skin, bone marrow and lymph nodes.

Findings from the CADENZA study were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting by Naveen Pemmaraju, who led the trial together with Naval Daver.

As a frontline treatment in 33 newly diagnosed patients with BPDCN, researchers observed an overall response rate of 85%, including a complete response rate of 70% with a median overall survival of 16.6 months.

“Patients with BPDCN are in need of improved frontline therapies to treat their disease, so we’re very excited to see this trial going extremely well in terms of safety and efficacy,” Pemmaraju said. “The responses we have observed make PVEK a strong candidate as a standard-of-care treatment.”

The current standard-of-care treatment for patients with BPDCN is tagraxofusp-erzs, which targets CD123 found at high levels on certain cancer cells, including BPDCN. MD Anderson researchers helped advance tagraxofusp-erzs toward Food and Drug Administration approval in 2018.

PVEK represents a next generation of CD123-targeted treatment. As an ADC, it works by delivering a drug directly to cancer cells by targeting CD123 on the surface of BPDCN cells, resulting in death of the cancer cells.

The global multi-center trial enrolled a total of 84 adult patients with CD123-positive BPDCN. Of these patients, 33 patients were newly diagnosed, and 51 patients had relapsed or refractory BPDCN with one, two or three prior lines of therapy. Participants received the therapy intravenously on day one of a 21-day cycle in an outpatient setting.

The most common side effects included peripheral edema, which was reversible and found to be manageable.

Given the results of this trial, there is potential for investigating combination therapies of CD123-targeted agent PVEK with other treatments active in BPDCN in future clinical trials, Pemmaraju explained.

The clinical trial was funded by AbbVie. Pemmaraju has served on the advisory board and as a consultant for AbbVie. Daver has received research support and has served on the advisory board and as a consultant for AbbVie.

More information:
Abstract: meetings.asco.org/abstracts-presentations/244202

Provided by
University of Texas M. D. Anderson Cancer Center


Citation:
Antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer (2025, June 2)
retrieved 2 June 2025
from https://medicalxpress.com/news/2025-06-antibody-drug-conjugate-safety-response.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.


Tags: Health ResearchHealth Research NewsHealth ScienceMedicine ResearchMedicine Research NewsMedicine Science
Previous Post

To avoid blackouts, Trump admin keeps another aging power plant online through summer

Related Posts

Arizona Man Died After Months of Failed Attempts to Access Mental Health Care. Now His Mother Is Suing His Insurer

June 2, 2025
4
Viz.ai, Novartis partner for AI-powered care for patients with cancer

Viz.ai, Novartis partner for AI-powered care for patients with cancer

June 2, 2025
5
  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024

Police ID man who died after Corso Italia fight

December 23, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
To avoid blackouts, Trump admin keeps another aging power plant online through summer

To avoid blackouts, Trump admin keeps another aging power plant online through summer

June 2, 2025
ICE boosting tip line after antisemitic attack by visa overstayer in Boulder

ICE boosting tip line after antisemitic attack by visa overstayer in Boulder

June 2, 2025
US Indo-Pacific commander calls PLA operations in Taiwan Strait ‘rehearsals’, not just exercises

US Indo-Pacific commander calls PLA operations in Taiwan Strait ‘rehearsals’, not just exercises

June 2, 2025
Russia and Ukraine fail again to agree ceasefire but commit to prisoner swap

Russia and Ukraine fail again to agree ceasefire but commit to prisoner swap

June 2, 2025

Recent News

To avoid blackouts, Trump admin keeps another aging power plant online through summer

To avoid blackouts, Trump admin keeps another aging power plant online through summer

June 2, 2025
0
ICE boosting tip line after antisemitic attack by visa overstayer in Boulder

ICE boosting tip line after antisemitic attack by visa overstayer in Boulder

June 2, 2025
4
US Indo-Pacific commander calls PLA operations in Taiwan Strait ‘rehearsals’, not just exercises

US Indo-Pacific commander calls PLA operations in Taiwan Strait ‘rehearsals’, not just exercises

June 2, 2025
2
Russia and Ukraine fail again to agree ceasefire but commit to prisoner swap

Russia and Ukraine fail again to agree ceasefire but commit to prisoner swap

June 2, 2025
3

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

ICE boosting tip line after antisemitic attack by visa overstayer in Boulder

ICE boosting tip line after antisemitic attack by visa overstayer in Boulder

June 2, 2025
US Indo-Pacific commander calls PLA operations in Taiwan Strait ‘rehearsals’, not just exercises

US Indo-Pacific commander calls PLA operations in Taiwan Strait ‘rehearsals’, not just exercises

June 2, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co